BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today highlighted the growing trend across the U.S. payer landscape of coverage policies that allow appropriately trained nurse practitioners to administer Transcranial Magnetic Stimulation (TMS) therapy. A growing number of commercial insurers, Medicare Administrative Contractors (MACs), and government payers now permit psychiatric mental health nurse practitioners (PMHNPs) to administer TMS therapy, including Deep TMS™, when practicing in accordance with applicable regulations and state scope‑of‑practice requirements.
Among large U.S. payers, Optum/United Behavioral Health (“Optum Behavioral Health”) updated its TMS clinical policy in late 2025 to explicitly allow PMHNPs to order, supervise, and administer TMS therapy in states that grant them full practice authority, where such services fall within advanced practice registered nurse scope of practice. Previously, this authority had been limited to psychiatrists under the policy. The updated Optum Behavioral Health policy applies to commercial plans covering approximately 34.8 million lives.
In addition to Optum, multiple other U.S. commercial payers, MACs (including First Coast, National Government Services, and Novitas), the U.S. Department of Veterans Affairs, and TRICARE West have all adopted similar coverage approaches increasing the role of nurse practitioners providing TMS care, subject to compliance with applicable policy and regulatory frameworks.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.